Sylvester Comprehensive Cancer Center

  • 20230173 - Jonczak Emily

  • Investigator:
    Emily Jonczak
    RCname Email

    Coordinator:

    IRB: 20230173

    SDG: Bone and Soft Tissue (Sarcoma)
    Disease Site(s):

    Soft Tissue

    Sponsor: Shanghai Pharma Biotherapeutics USA Inc

    Enrolling Sites:

    Plantation
    Sylvester

    Title:

    A Phase 2 Multicenter, Open-Label Study Of The CDK4/6 Inhibitor SPH4336 In Subjects With Locally Advanced Or Metastatic Liposarcomas

    Eligibility Criteria - NCT05580588 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231142 - Jonczak Emily

  • Investigator:
    Emily Jonczak
    RCname Email

    Coordinator:

    IRB: 20231142

    SDG: Bone and Soft Tissue (Sarcoma)
    Disease Site(s):

    Soft Tissue

    Sponsor: POLARIS PHARMACEUTICALS

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double-Blind, Multi-Center Phase 3 Trial

    Eligibility Criteria - NCT05712694 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201368 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    Coordinator:

    IRB: 20201368

    SDG: Bone and Soft Tissue (Sarcoma)
    Disease Site(s):

    Multiple

    Sponsor: SCCC

    Enrolling Sites:

    Plantation
    Sylvester

    Title:

    ctDNA-Guided Sunitinib And Regorafenib Therapy for Gastrointestinal Stromal Tumor (GIST)

    Eligibility Criteria - NCT05366816 *This information has been extracted from " www.clinicaltrials.gov"

  • 20211225 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    Coordinator:
    RCemailImg Ravipal Luthra
    RCphone +1 (305) 2438266

    IRB: 20211225

    SDG: Bone and Soft Tissue (Sarcoma)
    Disease Site(s):

    Multiple

    Sponsor: Cogent Biosciences

    Enrolling Sites:

    Sylvester

    Title:

    (PEAK) A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF CGT9486+SUNITINIB VS SUNITINIB IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC GASTROINTESTINAL STROMAL TUMORS

    Eligibility Criteria - NCT05208047 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220946 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    Coordinator:

    IRB: 20220946

    SDG: Bone and Soft Tissue (Sarcoma)
    Disease Site(s):

    Bones and Joints

    Sponsor: ADVENCHEN LABORATORIES

    Enrolling Sites:

    Sylvester

    Title:

    An Open Label Post-Trial Access (PTA) of Catequentinib (AL3818, Anlotinib) Hydrochloride Mono or in Combination Therapies in Patients Who Have Completed an Advenchen Sponsored Oncology Study with AL3818 (A Compassionate Use Trial)

    Eligibility Criteria - NCT05612191 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230891 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    Coordinator:

    IRB: 20230891

    SDG: Bone and Soft Tissue (Sarcoma)
    Disease Site(s):

    Bones and Joints,Soft Tissue

    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester

    Title:

    A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination with Anticancer Therapies in Participants with Advanced Malignancies

    Eligibility Criteria - NCT05957367 *This information has been extracted from " www.clinicaltrials.gov"